Andrew Nixon, PhD, MBA (Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.
Education and Training
- M.B.A., Duke University, 2007
- Ph.D., Wake Forest University, 1997
Grants
- Integrated analysis of a NLRP3-dependent adaptive resistance mechanism to pembrolizumab immunotherapy in advanced gastroesophageal cancer
- IL-6 in PDIGREE (AO31704)
- A Randomized Phase 2 Trial to Evaluate Prebiotic Intervention in Allogeneic Hematopoietic Stem Cell Transplantation
- Clinical Biomarker Study of the Tumor NLRP3 Inflammasome and its Role in Anti-PD-1 Immunotherapy Resistance
- Anti-PD1 in combination with an inhibitor of PCSK9 to increase MHC class I molecule expression on tumor cells as immunotherapy for NSCLC
- Printed Electronic Biosensors for Point-of-Care Testing of Cardiovascular Biomarkers
- Immune signatures in metastatic colorectal cancer
- Identification and validation of plasma-based protein biomarkers for cediranib and olaparib in GY005, phase III
- Mountaineer Biomarker Study: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HET2+ Metastatic Colorectal Cancer.
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
- Single-cell cytokine profiling in metastatic colorectal cancer patients receiving immunotherapy
- Angiogenic biomarker discovery to direct bevacizumab therapy in cervical cancer - Blood-based Angiome Profiling: An ancillary analysis of GOG-0240
- Home Transplant to Preserve the Microbiota and Decrease GVHD
- A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer
- Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer
- MSI in mCRC
- Cell-Free DNA for Diagnosis of Malignancy, Genetic Mutations and Prognosis in Lung Cancer Related Pleural Effusions
- Brain Vasular Malformation Consortium: Predictors of clinical course